Slide 1: Dexcom earnings Q1 2023
bpexcom Dexcom earnings Q1 2023
Slide 2: Safe Harbor Statement
Safe Harbor Statement pexcom This presentation contains "forward" looking statements that are based on our management's beliefs and assumptions and on information currently available to management. We intend for such forward-looking statements to be covered by the safe harbor provisions for forward-
Slide 3: First quarter 2023
First quarter 2023 idl © Strong growth with Key Financial Strategic $741 million in revenue Highlights Highlights 19% organic revenue growth! Delivered record first quarter Initiated full launch of Dexcom G7 in (17% US; 27% OUS?) free cash flow the US Generated over 250 basis points Significant expa
Slide 4: First quarter performance
First quarter performance Total Revenue & Organic Growth Rate! ($MM) $800 $629 $696 $770 $815 $741 $600 $400 $200 SKS +16% +20% +20% +19% $0 Ql22 Q2'22 Q3'22 Q4'22 Q123 Non-GAAP Operating Margin” 25% 20.9% 21.1% 20% 14.6% 18% . 10.6% 10% 8.0% - = 0% Q122 Q2'22 Q3'22 Q4'22 Q123 1. Excludes non-CGM re
Slide 5: 2023 Guidance as of April 27, 2023
2023 Guidance as of April 27, 2023 2023 Annual Revenue and Profitability Guidance Non-GAAP Non-GAAP Adjusted Revenue Gross Profit Margin* Operating Margin* EBITDA Margin* . USD Previous 3.350-3.490 62-63% ~16.5% ~26% billion USD Updated 3.400-3.515 62-63% ~16.5% ~26% billion “Adjusted EBITDA defined
Slide 6: Appendix: Revenue Data and GAAP Reconciliations
bexcom Appendix Revenue Data and GAAP Reconciliations
Slide 7: GAAP to non-GAAP reconciliations
Three Months Ended March 31, Three Months Ended March 31, (In millions) 2023 2022 (In millions, except per share data) 2023 2022 GAAP gross profit $ 462.6 $ 398.1 GAAP net income $ 48.6 $ 97.3 Amortization of intangible assets (1) 7.2 — Amortization of intangible assets (1) 9.0 2.0 Non-GAAP gross pr
Slide 8: Revenue Metrics By Component
Q1'20 Q2'20 Q3'20 Q4'20 Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Revenue Metrics By Component Sensor & Other Revenue (millions) (1) (2) $ 325.0 $ 364.5 $ 406.3 $ 465.6 $ 424.3 $ 494.5 $ 547.9 $ 598.6 $ 543.2 $ 597.7 $ 666.6 $ 714.8 $ 651.9 Year over year growth 53% 40% 28% 30% 31% 36% 3
Slide 9: Revenue Metrics By Geography
Q1'20 Q2'20 Q3'20 Q4'20 Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Revenue Metrics By Geography US Revenue (millions) $ 292.3 $ 367.1 $ 398.6 $ 451.5 $ 381.2 $ 461.5 $ 489.6 $ 517.1 $ 451.2 $ 511.0 $ 573.4 $ 606.4 $ 526.0 Year over year growth 39% 38% 29% 20% 30% 26% 23% 15% 18% 11% 17% 1
Slide 10: Organic Revenue
Q1'20 Q2'20 Q3'20 Q4'20 Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 1 Organic Revenue OUS Revenue - Reported $ 112.8 $ 84.7 $ 102.3 $ 117.4 $ 123.8 $ 133.6 $ 160.6 $ 181.1 $ 177.6 $ 185.2 $ 196.2 $ 208.8 $ 215.5 Impact of Acquired Revenue and Foreign Exchange 1.1 1.1 (2.4) (3.3) (5.4) (7.3
Slide 11: Definitions
DexCom, Inc. Definitions: Amortization of intangible assets — We are required by GAAP to record the fair values of the intangible assets of the entity on our balance sheet and amortize them over their useful ives. We exclude these non-cash amortization charges related to acquired intangible assets f